Video yรผkleniyor...

Video Yรผklenemedi

Ana Sayfaya Dรถn

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: KeloniaTx presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation. Full video:

BiotechTV's profile picture

BiotechTV

11,963 subscribers

21,980 gรถrรผntรผleme โ€ข 9 ay รถnce โ€ขvia X (Twitter)

LIVE

Anya Rossiโ€ข Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gรถnderinin yorumlarฤฑ burada gรถrรผnecek

Benzer Videolar

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Checking in (quickly) with Terns Pharmaceuticals CEO Amy Burroughs on the tern-701 data at ASH. $TERN
5:58

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Checking in (quickly) with Terns Pharmaceuticals CEO Amy Burroughs on the tern-701 data at ASH. $TERN

BiotechTV

18,704 gรถrรผntรผleme โ€ข 9 ay รถnce

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know. $CRVS Full video:
3:33

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know. $CRVS Full video:

BiotechTV

17,673 gรถrรผntรผleme โ€ข 9 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:
5:19

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:

BiotechTV

22,484 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐€๐’๐‚๐Ž ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-ฮฒ with EGFR for its fusion protein in HPV negative head & neck. $BCAX #ASCO26 Full video:
1:56

๐€๐’๐‚๐Ž ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-ฮฒ with EGFR for its fusion protein in HPV negative head & neck. $BCAX #ASCO26 Full video:

BiotechTV

11,745 gรถrรผntรผleme โ€ข 3 ay รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:
4:17

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:

BiotechTV

18,780 gรถrรผntรผleme โ€ข 10 ay รถnce

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:
3:45

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:

BiotechTV

11,057 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“ ๐•๐ž๐ง๐ญ๐ฎ๐ซ๐ž ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ: Every year at this time, HSBC Innovation Banking's Jon Norris publishes his widely-read full year venture report. DOWNLOAD THE FREE REPORT HERE: HSBC Innovation Banking | #sponsored
1:06

๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“ ๐•๐ž๐ง๐ญ๐ฎ๐ซ๐ž ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ: Every year at this time, HSBC Innovation Banking's Jon Norris publishes his widely-read full year venture report. DOWNLOAD THE FREE REPORT HERE: HSBC Innovation Banking | #sponsored

BiotechTV

16,954 gรถrรผntรผleme โ€ข 8 ay รถnce

๐…๐ซ๐จ๐ฆ ๐ญ๐ก๐ž ๐๐š๐ฒ ๐€๐ซ๐ž๐š: Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity. Co Founder & CSO Martin Borch Jensen explains how it works. Full video:
2:56

๐…๐ซ๐จ๐ฆ ๐ญ๐ก๐ž ๐๐š๐ฒ ๐€๐ซ๐ž๐š: Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity. Co Founder & CSO Martin Borch Jensen explains how it works. Full video:

BiotechTV

13,213 gรถrรผntรผleme โ€ข 7 ay รถnce

๐๐ˆ๐Ž ๐ˆ๐ง๐ญ๐ž๐ซ๐ง๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Ocugen CEO Shankar Musunuri discusses the company's gene therapy platform for eye conditions - one of which is already in a pivotal, with another to start. #BIO2025 $OCGN Full video:
3:57

๐๐ˆ๐Ž ๐ˆ๐ง๐ญ๐ž๐ซ๐ง๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Ocugen CEO Shankar Musunuri discusses the company's gene therapy platform for eye conditions - one of which is already in a pivotal, with another to start. #BIO2025 $OCGN Full video:

BiotechTV

13,873 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ’: Legend Biotech CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more. #ASH24 $LEGN Full video:
0:48

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ’: Legend Biotech CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more. #ASH24 $LEGN Full video:

BiotechTV

17,521 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:
3:01

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

BiotechTV

22,305 gรถrรผntรผleme โ€ข 2 ay รถnce

๐€๐’๐†๐‚๐“ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account by Kiran Musunuru. #ASGCT2025 Full video:
10:34

๐€๐’๐†๐‚๐“ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account by Kiran Musunuru. #ASGCT2025 Full video:

BiotechTV

22,313 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: Dana-Farber investigators Toni Choueiri, MD and Patrick Ott describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur. Full video:
4:28

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: Dana-Farber investigators Toni Choueiri, MD and Patrick Ott describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur. Full video:

BiotechTV

13,805 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

Aero shouldn't be making that much of a difference at a short track. Do you think the Next Gen car was too tough to pass with in Iowa?
0:58

Aero shouldn't be making that much of a difference at a short track. Do you think the Next Gen car was too tough to pass with in Iowa?

Dirty Mo Media

16,078 gรถrรผntรผleme โ€ข 1 ay รถnce

The opening track from our Deep Set at Group Therapy 600 in Mexico City, Tim Green's remix of 'Homecoming' is out today on Anjunabeats. The full set will be available to hear in full on streaming services from Monday 13 July.
0:54

The opening track from our Deep Set at Group Therapy 600 in Mexico City, Tim Green's remix of 'Homecoming' is out today on Anjunabeats. The full set will be available to hear in full on streaming services from Monday 13 July.

Above & Beyond

10,431 gรถrรผntรผleme โ€ข 2 ay รถnce

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:
13:02

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:

BiotechTV

68,717 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

Company News: Intellia Therapeutics's Chief Scientific Officer elaborates on the news that the company successfully redosed patients with a CRISPR-based and LNP delivered therapy. $NTLA Full video:
4:26

Company News: Intellia Therapeutics's Chief Scientific Officer elaborates on the news that the company successfully redosed patients with a CRISPR-based and LNP delivered therapy. $NTLA Full video:

BiotechTV

21,950 gรถrรผntรผleme โ€ข 2 yฤฑl รถnce

Freak visuals from Ludhiana in Punjab. A man stole a Baleno car. He was intercepted and cornered. What happened next? Multiple speeding laps in forward and reverse - ramming into anything that came its way on the narrow road.
2:15

Freak visuals from Ludhiana in Punjab. A man stole a Baleno car. He was intercepted and cornered. What happened next? Multiple speeding laps in forward and reverse - ramming into anything that came its way on the narrow road.

Piyush Rai

160,266 gรถrรผntรผleme โ€ข 5 ay รถnce